Abuse resistant lysine amphetamine compounds

Abstract

The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

1 .- 35 . (canceled) 
     
     
         36 . A method of treating a subject with obesity, the method comprising orally administering to the subject, a therapeutically effective amount of L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof. 
     
     
         37 . The method of  claim 36 , wherein the L-lysine-d-amphetamine or a pharmaceutically acceptable salt thereof is in a dosage form selected from the group consisting of a tablet, a capsule, a caplet, an oral solution, or an oral suspension. 
     
     
         38 . The method of  claim 36 , wherein the L-lysine-d-amphetamine is in the form of a salt. 
     
     
         39 . The method of  claim 38 , wherein the salt is a mesylate salt. 
     
     
         40 . The method of  claim 38 , wherein the salt is a hydrochloride salt. 
     
     
         41 . The method of  claim 36 , wherein the therapeutically effective amount is an amount sufficient to provide a therapeutically bioequivalent AUC when compared to amphetamine alone, but which does not provide a C max  which results in euphoria. 
     
     
         42 . The method of  claim 37 , wherein the therapeutically effective amount in the dosage form is from about 5 mg to about 500 mg of the L-lysine-d-amphetamine or a salt thereof. 
     
     
         43 . The method as defined in  claim 42 , wherein the dosage form is administered one or more times per 24-hour period.